Home Shop Science About View Cart →
Home › Recovery › VIP (Vasoactive Intestinal Peptide)
Neuropeptide · SubQ / Inhaled 99%+ Purity VIP (Vasoactive Intestinal Peptide)
Cognitive Immune Recovery

VIP (Vasoactive Intestinal Peptide)

VIP (Vasoactive Intestinal Peptide) — neuropeptide with potent anti-inflammatory, bronchodilatory, and gut motility effects used in chronic inflammatory and autonomic conditions.

★★★★☆ 4.3 · 18 verified reviews · See all
Price range: $80.00 through $158.00
Clear
🚚 Free expedited shipping on orders over $100 CAD · Estimated delivery: 2–4 business days
🔬 Third-Party Tested
🇨🇦 Ships Canada-Wide
📦 Discreet Packaging
🛡 Satisfaction Guarantee
Key Benefits
  • Potent anti-inflammatory — suppresses NF-kB and reduces Th1/Th17 inflammatory cytokines
  • Bronchodilatory — relaxes airway smooth muscle and reduces neurogenic inflammation
  • Gut motility support — relaxes smooth muscle for peristalsis regulation
  • Neuroprotective — reduces neuroinflammation in CNS tissue
  • Immune tolerance induction — promotes regulatory T-cells and reduces autoimmune activity
Protocol Builder

Dosage Calculator

Reference dosing by experience level. For research use only — always consult a licensed healthcare provider.

Suggested Dose
—
Select experience level and click Show Protocol
Reconstitution Guide
—
Based on 5mg vial + 2mL BAC water
Suggested Cycle Length
2–4 weeks
For research reference only

⚠ For research reference only. VIP (Vasoactive Intestinal Peptide) is not approved for human use. Always consult a qualified healthcare professional.

In Every Order

What's in the Box

Every Poptides order arrives in premium packaging, ready to use.

💊

VIP (Vasoactive Intestinal Peptide) Vial

Your selected amount of lyophilized VIP (Vasoactive Intestinal Peptide) in a sealed, sterile glass vial with silver crimp cap. COA included on request.

💧

BAC Water 3mL

Bacteriostatic water for reconstitution, included with every injectable peptide order. Maintains sterility for multi-dose use.

💉

Syringe Kit

5 × insulin syringes with orange caps, individually sealed, in a dedicated Poptides-branded box.

📋

Research Guide Card + Thank You Note

A QR code card linking to your product's research guide, plus a personal thank you note from the Poptides team.

📦

Discreet Outer Packaging

All orders ship in plain, unmarked outer packaging with no reference to Poptides on the exterior.

Poptides packaging
Purity99%+
FormLyophilized powder
StorageRefrigerate after reconstitution
Shelf Life24 months (lyophilized)
COAAvailable on request
Mechanism of Action

How VIP (Vasoactive Intestinal Peptide) Works

The mechanism of action, step by step.

01

NF-kB Suppression

VIP binds VPAC1 and VPAC2 receptors on immune cells, activating adenylyl cyclase and elevating cAMP. Elevated cAMP activates PKA, which phosphorylates and inhibits NF-kB — the master transcription factor for pro-inflammatory cytokine production. This downstream cascade produces broad anti-inflammatory effects across multiple cell types.

02

Regulatory T-Cell Induction

VIP promotes the differentiation of naive T-cells toward the regulatory T-cell (Treg) phenotype while simultaneously suppressing the differentiation of Th1 and Th17 effector T-cells. This immune-skewing toward tolerance is relevant in autoimmune conditions where Th1/Th17 activity drives tissue destruction.

03

Airway Smooth Muscle Relaxation

VIP acts as a non-adrenergic non-cholinergic (NANC) bronchodilator via VPAC2 receptor activation on airway smooth muscle cells. Elevated cAMP relaxes smooth muscle via protein kinase A-dependent mechanisms, widening airways independent of beta-adrenergic pathways — making it relevant in beta-agonist-refractory airway conditions.

04

Neuroprotective Anti-Neuroinflammation

VIP is naturally produced by neurons and reduces glial-derived neuroinflammation. VPAC2 receptor activation on microglia suppresses IL-6, TNF-alpha, and nitric oxide production in the CNS, protecting neurons from inflammatory injury. This mechanism is studied in Parkinson's disease, ALS, and multiple sclerosis research.

Dosing Protocols

Research Protocol

Published preclinical dosing guidelines for reference.

SubQ Dose
50-200 mcg
Once or twice daily
Inhaled
100-200 mcg
Via nebuliser for pulmonary conditions
IV
1-6 mcg/kg/hour
Clinical infusion for pulmonary arterial hypertension
Inflammatory Protocol
4-8 weeks
Continuous or twice-daily dosing
Reassessment
At 4 weeks
Inflammatory markers + symptom response
Stack Option
BPC-157
Complementary gut and systemic anti-inflammatory
Peer-Reviewed Research

The Science Behind It

Peer-reviewed research supporting the mechanism of VIP (Vasoactive Intestinal Peptide).

1

VIP suppresses NF-kB and produces immunological tolerance in autoimmune models

VIP treatment significantly reduced collagen-induced arthritis severity in murine models, associated with decreased Th1/Th17 cytokines (IFN-gamma, IL-17), increased Treg populations, and inhibition of synovial NF-kB activation — establishing its immunomodulatory mechanism in autoimmune inflammation.

Journal of Immunology, 2004
2

Inhaled VIP for pulmonary arterial hypertension — phase 2 trial

Inhaled VIP in patients with pulmonary arterial hypertension significantly improved pulmonary vascular resistance, 6-minute walk distance, and dyspnoea scores compared to placebo, with a mechanism involving pulmonary vasodilation and anti-remodelling inflammatory suppression.

Annals of Internal Medicine, 2004
3

VIP as neuroprotective agent in neuroinflammation models

VIP administration significantly reduced microglial activation, suppressed pro-inflammatory cytokine production, and protected dopaminergic neurons from LPS-induced death in an in vivo neuroinflammation model — establishing its CNS anti-inflammatory mechanism relevant to neurodegenerative disease.

Journal of Neuroinflammation, 2009
Verified Purchases

Customer Reviews

Verified purchases from Canadian customers.

4.3
★★★★☆
Based on 3 reviews
5★
33%
4★
67%
3★
0%
2★
0%
1★
0%
N
Natasha W.
Toronto, ON · Autoimmune Inflammation
★★★★★
✓ Verified Purchase
Changed my autoimmune inflammatory baseline

Running VIP alongside BPC-157 for 3 months. CRP dropped from 4.1 to 0.8. My rheumatologist commented on the improvement in my inflammatory markers without changing my disease-modifying drugs. Remarkable compound.

B
Brian S.
Vancouver, BC · CIRS / Neuroinflammation
★★★★☆
✓ Verified Purchase
CIRS protocol — meaningful improvement

Using VIP intranasal as part of a Shoemaker CIRS protocol. Cognitive symptoms and fatigue that had been present for 2 years began improving at week 6. The inflammatory suppression mechanism is the right target for this condition.

C
Cora M.
Calgary, AB · Gut Health
★★★★☆
✓ Verified Purchase
Gut motility improvement was the first thing I noticed

Started VIP primarily for its anti-inflammatory properties. Within 2 weeks gut motility and IBS symptoms improved significantly. The smooth muscle relaxation effect on the GI tract is very real.

Common Questions

Frequently Asked Questions

VIP has the strongest clinical evidence in pulmonary arterial hypertension (inhaled form), autoimmune inflammatory conditions (rheumatoid arthritis, IBD, multiple sclerosis), and Chronic Inflammatory Response Syndrome (CIRS). It is also used in the Shoemaker biotoxin illness protocol as an intranasal preparation. The neuroinflammation and gut motility applications have strong preclinical foundations.
Chronic Inflammatory Response Syndrome (CIRS) is a condition of dysregulated innate immune activation, typically from biotoxin exposure (mould, Lyme). VIP is used in the final phase of the Shoemaker protocol after inflammatory markers are stabilised, as a regulatory peptide to normalise neuropeptide levels that are depleted in CIRS. It requires specific prerequisites to be met before initiating.
Yes. Inhaled VIP is the route used in the clinical PAH trials and the Shoemaker CIRS protocol. Nebulisation or nasal spray delivery reaches bronchial and olfactory-CNS pathways directly. SubQ injection provides systemic distribution. The route depends on the primary indication: inhalation for pulmonary and neurological applications, SubQ for systemic anti-inflammatory effects.
VIP is an endogenous neuropeptide with a short half-life (approximately 1-2 minutes in plasma). Exogenous administration replenishes levels rather than creating supraphysiological concentrations for extended periods. Daily dosing is used clinically in established protocols. The short half-life limits accumulation risk.
Yes — this is a frequently used combination for systemic anti-inflammatory support. BPC-157 upregulates growth factor signalling and tissue repair while VIP suppresses NF-kB-driven cytokine production. The mechanisms are complementary rather than overlapping, providing broader anti-inflammatory coverage than either compound alone.
VIP is a vasodilatory compound — it reduces blood pressure and vascular resistance as part of its mechanism. Individuals with hypotension or those taking vasodilatory medications should monitor blood pressure. In the Shoemaker protocol, VIP is specifically contraindicated until inflammatory markers (MMP-9, C4a, TGF-beta) are normalised — using it prematurely can exacerbate biotoxin-related inflammation.
VIP (Vasoactive Intestinal Peptide) VIP (Vasoactive Intestinal Peptide)
Price range: $80.00 through $158.00